SBIR Phase II (COVID-19): Highly Potent Nanozeolite-based Silver Antimicrobials

SBIR II 期 (COVID-19)：高效纳米沸石银抗菌剂

• 批准号: 2025819
• 负责人: Bo Wang
• 金额: $ 100万
• 依托单位: ZeoVation, Inc.
• 依托单位国家: 美国
• 项目类别: Cooperative Agreement
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-15 至 2024-08-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2025819&HistoricalAwards=false
• 关键词: SBIR; Phase; II; COVID; 19

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is to provide a long-lasting antimicrobial and antiviral solution for medical, military and consumer applications. Antibiotic resistance has increased the prevalence of hospital-acquired infections, and the novel coronavirus SARS-CoV-2 has caused a worldwide COVID-19 pandemic. This project seeks to mitigate these problems by developing a technology to effectively decrease the transfer of bacteria and viruses via contaminated surfaces. This antimicrobial surface coating technology kills pathogens and minimizes their transport; it can be used in medical and healthcare institutions to support contagion mitigation efforts. This Small Business Innovation Research (SBIR) Phase II project will scale up manufacturing of a silver/zinc ion nanozeolite via a method to produce a spray product. Formulations that can be easily and uniformly applied on soft and hard surfaces by optimal choice of additives will be developed. Two unique features of the spray are increased adhesion of the active nanozeolite to a surface as well as the ability to predict when the activity of the nanozeolite is diminished by visual observations, prompting the reapplication process. Uniform spreading of the nanozeolite on a surface will be controlled by the viscosity of the spray and the design of the pump sprayer. This project will demonstrate efficacy against gram-negative, gram-positive bacteria, pathogenic fungi and coronaviruses, as well as developing application protocols.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）II期项目的更广泛的影响/商业潜力是为医疗，军事和消费者应用提供持久的抗菌和抗病毒解决方案。抗生素耐药性增加了医院获得感染的患病率，而新型的冠状病毒SARS-COV-2引起了世界各地的Covid-19大流行。 该项目旨在通过开发技术来通过受污染的表面有效减少细菌和病毒的转移来减轻这些问题。 这种抗菌表面涂料技术可杀死病原体并最大程度地减少其运输。它可以用于医疗和医疗机构中，以支持触发缓解工作。这项小型企业创新研究（SBIR）II期项目将通过生产喷雾产品的方法来扩展银/锌离子纳米唑。将开发可通过添加剂的最佳选择来轻松且均匀地应用于软表面上的配方。喷雾的两个独特特征是使活性纳米唑的粘附增加在表面上，以及预测纳米唑啉何时通过视觉观测减少的活性，从而促使重新涂后过程。纳米二组利在表面上的均匀扩散将由喷雾的粘度和泵喷雾器的设计控制。该项目将证明针对革兰氏阴性，革兰氏阴性细菌，致病性真菌和冠状病毒以及制定应用程序方案的功效。该奖项反映了NSF的法定任务，并被认为是值得通过基金会的知识分子优点和更广泛影响的审查标准来通过评估来通过评估来支持的。